Clinical Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 18, 2025
Abstract
Background
There
have
been
conflicting
messages
about
the
influence
of
female
sex
hormones
on
women's
health,
with
historical
messaging
indicating
that
use
estrogen
and/or
progesterone
in
peri-
or
postmenopause
poses
a
significant
clinical
risk
to
cisgender
women.
More
recent
guidance
indicates
benefit
hormone
therapy
(HT)
outweighs
risks
for
symptomatic
Exogenous
is
also
indicated
contraception
and
gender-affirming
care.
Despite
potential
broad
applications,
robust
reference
intervals
estradiol,
progesterone,
luteinizing
(LH)
follicle-stimulating
(FSH)
are
lacking,
guidelines
indicate
measurement
17-β-estradiol
(E2),
LH,
FSH
does
not
facilitate
care
women
who
may
be
experiencing
menopausal
symptoms
taking
exogenous
HT.
Content
Here
we
review
physiological
roles
estrogen,
FSH.
We
examine
modes
administration
clarify
nomenclature
related
use,
comprehensively
literature
studies
evaluating
normal
concentrations
these
gonadal
axis
during
menstrual
cycle.
The
content
primarily
focuses
women,
but
some
aspects
transgender
will
discussed.
Summary
Currently,
E2,
FSH,
remain
incomplete.
Although
there
variety
indications
using
HT,
shared
decision-making
should
guide
Collaborative
efforts
between
clinicians
laboratory
professionals
better
define
therapeutic
can
advance
health
globally.
Antioxidants,
Journal Year:
2025,
Volume and Issue:
14(3), P. 324 - 324
Published: March 8, 2025
Twin
pregnancies,
with
higher
incidences
of
preterm
birth,
are
becoming
more
prevalent.
Progesterone
has
shown
effectiveness
in
the
prevention
labour,
though
other
factors
related
to
pregnancy
and
neonatal
health
may
be
affected
by
this
hormone
have
not
been
previously
addressed.
This
study
aims
evaluate
impact
progesterone
administration
on
oxidative
stress
bone
turnover
during
twin
gestation
investigate
associations
some
maternal/neonatal
variables
interest.
Women
pregnant
twins
were
recruited
"Virgen
de
la
Arrixaca"
University
Hospital
randomly
assigned
two
groups:
control
(n
=
49)
50).
A
total
600
mg/day
was
vaginally
administered
from
11
14
34
weeks
gestation.
Blood
samples
taken
first
(T1)
third
trimester
(T3),
analyzing
biomarkers
turnover.
Most
markers
experiment
significant
changes
significantly
increased
(p
<
0.05)
levels
osteocalcin
T3
decreased
sclerostin.
Regarding
stress,
group,
unlike
showed
no
increase
between
T1
T3.
In
conclusion,
results
show
that
could
maternal
formation
modulate
stress.
Clinical Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 18, 2025
Abstract
Background
There
have
been
conflicting
messages
about
the
influence
of
female
sex
hormones
on
women's
health,
with
historical
messaging
indicating
that
use
estrogen
and/or
progesterone
in
peri-
or
postmenopause
poses
a
significant
clinical
risk
to
cisgender
women.
More
recent
guidance
indicates
benefit
hormone
therapy
(HT)
outweighs
risks
for
symptomatic
Exogenous
is
also
indicated
contraception
and
gender-affirming
care.
Despite
potential
broad
applications,
robust
reference
intervals
estradiol,
progesterone,
luteinizing
(LH)
follicle-stimulating
(FSH)
are
lacking,
guidelines
indicate
measurement
17-β-estradiol
(E2),
LH,
FSH
does
not
facilitate
care
women
who
may
be
experiencing
menopausal
symptoms
taking
exogenous
HT.
Content
Here
we
review
physiological
roles
estrogen,
FSH.
We
examine
modes
administration
clarify
nomenclature
related
use,
comprehensively
literature
studies
evaluating
normal
concentrations
these
gonadal
axis
during
menstrual
cycle.
The
content
primarily
focuses
women,
but
some
aspects
transgender
will
discussed.
Summary
Currently,
E2,
FSH,
remain
incomplete.
Although
there
variety
indications
using
HT,
shared
decision-making
should
guide
Collaborative
efforts
between
clinicians
laboratory
professionals
better
define
therapeutic
can
advance
health
globally.
